戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  mRNA, and cAMP production induced by dDAVP (desmopressin).
2 d a lack of data on the newer formulation of desmopressin.
3 patients prescribed the older formulation of desmopressin.
4 fter water restriction and administration of desmopressin.
5 03 target genes, but only in the presence of desmopressin.
6 cortisone, sex steroids, growth hormone, and desmopressin.
7 onfirmed by treatment with the AC6 stimulant desmopressin.
8 binding assay, and no or partial response to desmopressin.
9 eibel-Palade body (WPB) secretagogues except desmopressin.
10 ical control in vivo, rats were treated with desmopressin.
11 d to patients prescribed this formulation of desmopressin.
12 c surgery can benefit from administration of desmopressin.
13 e treatment of patients unresponsive to this desmopressin.
14 d with more sustained improvements seen with desmopressin.
15 elective vasopressin type 2 receptor agonist desmopressin (1 nmol.kg(-1)) or continuous intravenous i
16                                              Desmopressin (1-deamino-8-d-arginine vasopressin [DDAVP]
17                                              Desmopressin (1-desamino-8-d-arginine vasopressin [DDAVP
18 signed (1:1) to a single dose of intravenous desmopressin 20 mug or matching placebo.
19 to vehicle-infused animals (3 +/- 2%) in the desmopressin (40 +/- 6%, p < .001) and arginine vasopres
20 tay of therapy for most patients with vWD in desmopressin, a pharmacologic agent that stimulates the
21 oratory test accurately predicts response to desmopressin, a trial test should always be performed in
22                              We administered desmopressin, a V2 receptor-specific agonist, to wild-ty
23 l regulation of ECV transfer and report that desmopressin, a vasopressin analogue, stimulated the upt
24  rats subjected to dehydration, treated with desmopressin acetate (dDAVP), or water loaded.
25 d formulation, the main active ingredient is desmopressin acetate, but the new formulation also conta
26         Patients were nearly unresponsive to desmopressin acetate, consistent with a lack of regulate
27 ants randomized to receive both exercise and desmopressin achieved normal (>50%) FVIII:C, 75 and 135
28 e first included two studies and showed that desmopressin administered to brain-dead patients was not
29 fold higher BT200 levels were required after desmopressin administration (p < 0.001).
30                     The cystogenic effect of desmopressin administration was markedly enhanced in Pkd
31 e suffered from marked polyuria resistant to desmopressin administration.
32 udy arms (desmopressin followed by exercise, desmopressin alone, exercise followed by desmopressin, a
33                                              Desmopressin altered the translation rate rather than th
34 ty, with a preserved aquaporin-2 response to desmopressin and an intact response to furosemide.
35    Some patients will require treatment with desmopressin and it is important to avoid 'overshoot' ia
36 ified 3,137 adults who were newly prescribed desmopressin and matched them to 3,137 adults who were n
37 tment of bleeding in VWD involves the use of desmopressin and plasma-derived VWF concentrates and a v
38 ng von Willebrand factor (VWF) concentrates, desmopressin, and anti-fibrinolytic agents as main tools
39 se, desmopressin alone, exercise followed by desmopressin, and exercise alone).
40 verage of 86%, 100%, and 75% for octreotide, desmopressin, and the structural analogue of desmopressi
41                                              Desmopressin can be useful only in a few type 2 cases co
42 per 1,000 person-years for adults prescribed desmopressin compared to 11 per 1,000 person-years for a
43 e enough to require replacement therapy with desmopressin (DDAVP) and/or von Willebrand factor (VWF)/
44 commendation to consider a single dose of IV desmopressin (DDAVP) for antiplatelet-associated intracr
45                                              Desmopressin (DDAVP) is often administered to correct fa
46 e in the population of older adults, whereas desmopressin (DDAVP) should be used cautiously.
47      The patient responded to large doses of desmopressin (dDAVP) which decreased urine volume from 1
48 10 to 50 micro M) potentiated the effects of desmopressin (DDAVP), prostaglandin E(2) (PGE(2)), and i
49 sence or presence of the vasopressin analog, desmopressin (dDAVP).
50                                              Desmopressin (DDAVP; 1-deamino-[d-Arg(8)]vasopressin) is
51          1-deamino-8-d-arginine vasopressin (desmopressin [DDAVP]) is clinically efficacious in patie
52                     The vasopressin analogue desmopressin (desamino-d-arginine(8) vasopressin, dDAVP,
53                                              Desmopressin did not affect vWF parameters.
54 cells to the synthetic vasopressin analogue, desmopressin, did not affect exosomal flotillin-1 or TSG
55           After 5 d of drinking 5% dextrose, desmopressin does not increase the osmolality of the uri
56 sensitivity of renal tubules, a reduction in desmopressin dose might be necessary in patients with ce
57 nd out whether patients who can benefit from desmopressin during cardiac surgery can be identified by
58 e for treatment of uremic bleeding including desmopressin, erythropoietin, and estrogens.
59 18.4%) were randomized to 1 of 4 study arms (desmopressin followed by exercise, desmopressin alone, e
60 ge effect was observed for the initiation of desmopressin for nocturnal enuresis (negative control ou
61 nts occurred in 12 (44%) participants in the desmopressin group and 13 (48%) participants in the plac
62 stroke (four [15%] of 27 participants in the desmopressin group and six [22%] of 27 participants in t
63 neumonia (one [4%] of 27 participants in the desmopressin group and six [22%] of 27 participants in t
64 urred in six (22%) of 27 participants in the desmopressin group and ten (37%) of 27 participants in t
65 ith the placebo group, patients who received desmopressin had less blood loss in 24 h (mean 624 [SD 2
66 potential risks facing adult patients taking desmopressin has taken on added importance because a new
67  need for a definitive trial to determine if desmopressin improves outcomes in patients with intracer
68 entify the mechanism of action and safety of desmopressin in the clinical setting.
69 in; and combined infusion of selepressin and desmopressin increased fluid accumulation to levels simi
70                               Interestingly, desmopressin increased the translation of seven glutathi
71                                              Desmopressin induced regulatory changes in SPAK variants
72 inhibit ristocetin induced aggregation after desmopressin infusion compared to baseline (p < 0.001).
73 ereas 1.35 ug/ml BT200 were needed 2 h after desmopressin infusion.
74                                      Because desmopressin is already deaminated at the N-terminal, it
75                                              Desmopressin is expensive and can cause vomiting, headac
76      The only approved AVP receptor agonist, desmopressin is indicated for the treatment of central d
77                                              Desmopressin is well tolerated by most patients, however
78                                              Desmopressin may reduce inhibitor risk by avoiding expos
79                                 Furthermore, desmopressin modulated both the full-length and truncate
80 y recruited and randomly assigned to receive desmopressin (n=27) or placebo (n=27).
81 ardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).
82 ld with exercise compared with 1.9-fold with desmopressin (noninferiority, P = .04).
83 llocated treatment (one participant assigned desmopressin only received part of the infusion).
84        VWF levels increased > 2.5-fold after desmopressin or endotoxin infusion (p < 0.001) and both
85 et aggregation (Multiplate) before and after desmopressin or endotoxin infusions in healthy volunteer
86 cludes increasing endogenous VWF levels with desmopressin or infusion of exogenous VWF concentrates (
87 ith spontaneous intracerebral haemorrhage to desmopressin or placebo to reduce the antiplatelet drug
88 orrhage who are taking antiplatelet drugs to desmopressin or placebo.
89 tients, particularly those not responding to desmopressin or requiring a sustained hemostatic correct
90 eating monosyptomatic enuresis refractory to desmopressin, prevalence of enuresis when screening larg
91 th mild hemophilia A (HA) may use intranasal desmopressin prior to sports participation.
92 n a patient with central diabetes insipidus, desmopressin reduced the excretion of ECVs derived from
93                      BEST PRACTICE ADVICE 9: Desmopressin releases von Willebrand factor as its prima
94 desmopressin, and the structural analogue of desmopressin, respectively.
95         Seven of these patients had a robust desmopressin response and significantly reduced VWF half
96                       However, predictors of desmopressin response have been recently identified, all
97 y/VWF:Ag or VWF propeptide/VWF:Ag ratios; or desmopressin responses between low VWF and normalized ty
98                            Administration of desmopressin resulted in only a modest effect on renal c
99  but the heterogenous biological response to desmopressin, showing large interindividual variation, m
100 racked exosomal AQP2 upregulation induced by desmopressin stimulation of kidney collecting duct cells
101 output and its role in patient selection for desmopressin therapy.
102  by exosomes was demonstrated: exosomes from desmopressin-treated cells stimulated both AQP2 expressi
103 in exosomal AQP2 concentration that followed desmopressin treatment of mice and a patient with centra
104        The main interventions described were desmopressin use, triiodothyronine and methylprednisolon
105 findings of a randomized trial of intranasal desmopressin vs a standardized, moderate-intensity aerob
106 ance because a new intranasal formulation of desmopressin was approved by the FDA in 2017.
107                                              Desmopressin was approved by the Food and Drug Administr
108 s with AVWS, effectiveness of treatment with desmopressin was assessed.
109               Use of an older formulation of desmopressin was associated with a marked increased rate
110                                           As desmopressin was ineffective, bleeding during vvECMO-ass
111              Standard weight-based dosing of desmopressin was used.
112 ts newly prescribed the older formulation of desmopressin were propensity-score (PS)-matched to patie
113 e care, clot ratios in patients who received desmopressin were similar to those in the untreated cont
114 he selective vasopressin V2 receptor agonist desmopressin were similarly investigated.
115  rate of hyponatremia was also observed with desmopressin when tamsulosin was the comparator (HR 12.1

 
Page Top